A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries

(2013) Emanuela Esposito et al.   CNS & Neurological Disorders-Drug Targets

Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice

(2012) Akbar Ahmad et al.   BRAIN BEHAVIOR AND IMMUNITY

Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy

(2012) Rita Citraro et al.   NEUROPHARMACOLOGY

Evidence for the role of PI3-kinase-AKT-eNOS signalling pathway in secondary inflammatory process after spinal cord compression injury in mice

(2011) Irene Paterniti et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

GW0742, a High-Affinity PPAR-δ Agonist, Mediates Protection in an Organotypic Model of Spinal Cord Damage

(2011) Emanuela Esposito et al.   SPINE

Antiinflammatory Activity of Melatonin in Central Nervous System

(2010) Emanuela Esposito et al.   Current Neuropharmacology

Predictors of Early Mortality After Traumatic Spinal Cord Injury

(2010) Abhay Varma et al.   SPINE

Anti-TNF therapy in the injured spinal cord

(2010) Emanuela Esposito et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Effects of Palmitoylethanolamide on Signaling Pathways Implicated in the Development of Spinal Cord Injury

(2008) T. Genovese et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors

(2008) Barbara Costa et al.   PAIN

Anti-Oxidant, Anti-Inflammatory and Anti-Allergic Activities of Luteolin

(2008) Günter Seelinger et al.   PLANTA MEDICA